No abstract available.
Gastrointestinal Stromal Tumors*

The optimal surgical procedure for treatment of gastrointestinal stromal tumors (GISTs) of the duodenum remains undefined. Therefore, various surgical procedures have been introduced as treatment options for duodenal GISTs. Due to the anatomical complexity, the laparoscopic approach has been considered as a contraindication. Especially for GISTs located at the second portion of the duodenum, a laparoscopic wedge resection is technically difficult to perform. We describe the surgical technique of laparoscopic wedge resection with hand-sewn closure for GISTs that involve the second portion of the duodenum.
Duodenum ; Gastrointestinal Stromal Tumors

No abstract available.
Gastrointestinal Stromal Tumors* ; Hemorrhage*

No abstract available.
Gastrointestinal Stromal Tumors*

Gastrointestinal Stromal Tumor (GIST) is uncommon disease with only about 3,000 to 6,000 cases diagnosed annually. Tumors can occur in any sites in gastrointestinal tract, especially in stomach (60-70%) and small intestine (20-30%) and in large intestine and oesophagus, sometime in omentum, mesenterium, behind peritonaeum, etc. The disease is common in male from 40 to 80 years old. GIST is detected randomly during examinations such as endoscopy, X-ray or CT scan of stomach, large intestine. Tumors have two kinds of cell: lozenge cell (70%) and epithelial cell (30%). GIST is divided into 4 stages. Each stage has suitable treatments as chemical therapy, radio therapy, and targeted therapy. For metastatic GIST, tumors can be removed by surgery. The 5 years survival rate is 34% in removal tumors and is 10% in remained tumors
Gastrointestinal Stromal Tumors ; Diagnosis

No abstract available.
Gastrointestinal Stromal Tumors*

No abstract available.
Extremities ; Gastrointestinal Stromal Tumors

No abstract available.
Gastrointestinal Stromal Tumors

Background: Gastrointestinal stromal tumors (GIST) is defined as specific, typically kit (CD117)-positive and CKIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation-driven mesenchymal tumors that can occur anywhere in the GI tract. GIST diagnosis relies heavily on immunohistomorphology. However, with the advent of molecular testing, the classification, diagnosis and targeted-therapy for gastrointestinal mesenchymal tumors have been greatly improved. In the Philippines, molecular testing is not yet readily available as in other countries. The local molecular profile of gastrointestinal stromal tumors is a point of investigation as treatment may be more tailored to the patients’ needs. Objective: This study aims to determine the prevalence of CKIT and PDGFRA mutations among formalin-fixed and paraffin embedded gastrointestinal stromal tumors and other gastrointestinal mesenchymal tumors in St. Luke’s Medical Center – Quezon City. Methods: A retrospective cross-sectional study of formalin fixed and paraffin embedded tumor samples diagnosed as Gastrointestinal Stromal Tumor from January 1, 2009 to December 31, 2017 will be analyzed for KIT and PDGFRA mutations. Result: The epidemiology of GIST remains constant in that mean age group is the 5th to 6th decade, with equal gender distribution, and stomach followed by small bowel are the most common sites. Mutational analysis of the GISTs showed predominantly KIT Exon 11 (47.83%) followed by CKIT Exon 9 (13.04%) and PDGFRA Exon 18 (10.87%). For KIT Exon 11, deletion is the most common mutations followed by point mutations. No mutation is detected in 47.83% of GISTs. Conclusion Mutational analysis for CKIT-PDGFRA is warranted among GIST patients, as it may significantly influence treatment protocol in our patients.
Gastrointestinal Stromal Tumors

Gastrointestinal stromal tumors (GIST) because of its rarity continues to be a curiosity for radiologists, surgeons and pathologist. These tumors are usually found in gastrointestinal tract (GIT) but account for less than 1% of GIT tumors. A 35-year-old male presented to us with complaints of painful micturation which on radiologic evaluation revealed a large mass in relation to urinary bladder. The tru-cut biopsy reported a low grade soft tissue tumour. The said mass was excised on laparotomy and sent for histopathological examination which reported as high grade GIST or a pleomorphic sarcoma as possibilities. Immuno-histochemistry finally confirmed the diagnosis of a GIST with CD 34 positive and C-Kit negative status. Approximately, 95% of GIST tumors are C-Kit positive and hardly 5% are C-Kit negative. C-Kit negative status makes this case report more worth reporting.
Gastrointestinal Stromal Tumors